Floatz logo

Bcma Targeted Car T-Cells

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) cohort.

Asset / SponsorPhaseRating
AMIFAMPRIDINE
National Center for Research Resources (NCRR)
Phase 3BB
HUMAN IMMUNOGLOBULINS
National Center for Research Resources (NCRR)
Phase 3BB
i10e
Laboratoire français de Fractionnement et de Biotechnologies
Phase 3B
PREDNISONE TABLETS
Fred Hutchinson Cancer Center
Phase 2CCC
CARMUSTINE
Fred Hutchinson Cancer Center
Phase 2CCC

View all 18 →

Same molecule, other indications

Bcma Targeted Car T-Cells is also rated in:

myasthenia gravisDormant
C
Indicative ·
39 / 100
View asset →
multiple sclerosisDormant
C
Indicative ·
39 / 100
View asset →
autoimmune encephalitisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →